BIRC5 and ovarian carcinoma: Since survivin is supposed to directly bind and inhibit initiator and effector caspases [22,25], the reduced expression of survivin in ovarian cancer cells after domatinostat treatment is considered to have contributed to the anti-cancer activities of domatinostat by lowering the threshold for apoptosis.